Cue Biopharma's Promising Future: A Comprehensive Buy Rating Justification
Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)
Cue Biopharma Analyst Ratings
Oppenheimer Maintains Outperform on Cue Biopharma, Maintains $10 Price Target
Oppenheimer Remains a Buy on Cue Biopharma (CUE)
Cue Biopharma (CUE) Gets a Buy From Stifel Nicolaus
Cue Biopharma Analyst Ratings
Piper Sandler Remains a Buy on Cue Biopharma (CUE)
Cue Biopharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)
Cue Biopharma (CUE) Gets a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Cue Biopharma (CUE)
Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Mirati Therapeutics (MRTX)
Piper Sandler Maintains Overweight on Cue Biopharma, Raises Price Target to $8
Cue Biopharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cue Biopharma (CUE), Zoetis (ZTS) and CymaBay Therapeutics (CBAY)
Cue Biopharma (CUE) Gets a Buy From Piper Sandler
JMP Securities Keeps Their Buy Rating on Cue Biopharma (CUE)
Oppenheimer Assumes Cue Biopharma at Outperform, Announces Price Target of $10
Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Corvus Pharmaceuticals (CRVS)